6x3l: Difference between revisions
From Proteopedia
Jump to navigationJump to search
m Protected "6x3l" [edit=sysop:move=sysop] |
No edit summary |
||
| (3 intermediate revisions by the same user not shown) | |||
| Line 1: | Line 1: | ||
==Sortilin-Progranulin Interaction With Compound 2== | |||
<StructureSection load='6x3l' size='340' side='right'caption='[[6x3l]], [[Resolution|resolution]] 2.70Å' scene=''> | |||
== Structural highlights == | |||
<table><tr><td colspan='2'>Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=6X3L OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=6X3L FirstGlance]. <br> | |||
</td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 2.7Å</td></tr> | |||
<tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=GOL:GLYCEROL'>GOL</scene>, <scene name='pdbligand=NAG:N-ACETYL-D-GLUCOSAMINE'>NAG</scene>, <scene name='pdbligand=UMJ:1-benzyl-3-tert-butyl-1H-pyrazole-5-carboxylic+acid'>UMJ</scene></td></tr> | |||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=6x3l FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=6x3l OCA], [https://pdbe.org/6x3l PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=6x3l RCSB], [https://www.ebi.ac.uk/pdbsum/6x3l PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=6x3l ProSAT]</span></td></tr> | |||
</table> | |||
<div style="background-color:#fffaf0;"> | |||
== Publication Abstract from PubMed == | |||
High-throughput screening methods have been used to identify two novel series of inhibitors that disrupt progranulin binding to sortilin. Exploration of structure-activity relationships (SAR) resulted in compounds with sufficient potency and physicochemical properties to enable co-crystallization with sortilin. These co-crystal structures supported observed SAR trends and provided guidance for additional avenues for designing compounds with additional interactions within the binding site. | |||
Identification of potent inhibitors of the sortilin-progranulin interaction.,Stachel SJ, Ginnetti AT, Johnson SA, Cramer P, Wang Y, Bukhtiyarova M, Krosky D, Stump C, Hurzy DM, Schlegel KA, Cooke AJ, Allen S, O'Donnell G, Ziebell M, Parthasarathy G, Getty KL, Ho T, Ou Y, Jovanovska A, Carroll SS, Pausch M, Lumb K, Mosser SD, Voleti B, Klein DJ, Soisson SM, Zerbinatti C, Coleman PJ Bioorg Med Chem Lett. 2020 Sep 1;30(17):127403. doi: 10.1016/j.bmcl.2020.127403. , Epub 2020 Jul 15. PMID:32738972<ref>PMID:32738972</ref> | |||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |||
[[Category: | </div> | ||
[[Category: | <div class="pdbe-citations 6x3l" style="background-color:#fffaf0;"></div> | ||
[[Category: | |||
==See Also== | |||
*[[Neurotensin receptor|Neurotensin receptor]] | |||
== References == | |||
<references/> | |||
__TOC__ | |||
</StructureSection> | |||
[[Category: Large Structures]] | |||
[[Category: Parthasarathy G]] | |||
[[Category: Soisson SM]] | |||
Latest revision as of 10:40, 23 October 2024
Sortilin-Progranulin Interaction With Compound 2
| ||||||||||||
